270 related articles for article (PubMed ID: 26176646)
1. Psychiatrist's adherence: a new factor in relapse prevention of schizophrenia. A randomized controlled study on relapse control through telemedicine system.
Spaniel F; Novak T; Bankovska Motlova L; Capkova J; Slovakova A; Trancik P; Matejka M; Höschl C
J Psychiatr Ment Health Nurs; 2015 Dec; 22(10):811-20. PubMed ID: 26176646
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of the information technology-aided program of relapse prevention in schizophrenia (ITAREPS): a randomized, controlled, double-blind study.
Španiel F; Hrdlička J; Novák T; Kožený J; Höschl C; Mohr P; Motlová LB
J Psychiatr Pract; 2012 Jul; 18(4):269-80. PubMed ID: 22805901
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of Information Technology Aided Relapse Prevention Programme in Schizophrenia excluding the effect of user adherence: a randomized controlled trial.
Komatsu H; Sekine Y; Okamura N; Kanahara N; Okita K; Matsubara S; Hirata T; Komiyama T; Watanabe H; Minabe Y; Iyo M
Schizophr Res; 2013 Oct; 150(1):240-4. PubMed ID: 23998952
[TBL] [Abstract][Full Text] [Related]
4. ITAREPS: information technology aided relapse prevention programme in schizophrenia.
Spaniel F; Vohlídka P; Hrdlicka J; Kozený J; Novák T; Motlová L; Cermák J; Bednarík J; Novák D; Höschl C
Schizophr Res; 2008 Jan; 98(1-3):312-7. PubMed ID: 17920245
[TBL] [Abstract][Full Text] [Related]
5. The Information Technology Aided Relapse Prevention Programme in Schizophrenia: an extension of a mirror-design follow-up.
Spaniel F; Vohlídka P; Kozený J; Novák T; Hrdlicka J; Motlová L; Cermák J; Höschl C
Int J Clin Pract; 2008 Dec; 62(12):1943-6. PubMed ID: 18795967
[TBL] [Abstract][Full Text] [Related]
6. A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse.
Beasley CM; Sutton VK; Hamilton SH; Walker DJ; Dossenbach M; Taylor CC; Alaka KJ; Bykowski D; Tollefson GD;
J Clin Psychopharmacol; 2003 Dec; 23(6):582-94. PubMed ID: 14624189
[TBL] [Abstract][Full Text] [Related]
7. Protocol for a systematic review of telephone delivered psychosocial interventions on relapse prevention, adherence to psychiatric medication and health risk behaviours in adults with a psychotic disorder.
Beck AK; Baker A; Turner A; Haddock G; Kelly PJ; Berry K; Bucci S
BMJ Open; 2015 Dec; 5(12):e009985. PubMed ID: 26700289
[TBL] [Abstract][Full Text] [Related]
8. [Education in schizophrenia: how patients and their relatives assess the relapse prevention programme PREDUKA].
Motlová LB; Dragomirecká E; Matelová S; Otevrelová R; Cermáková R; Cermák J; Lednická E; Hegedüsová R; Hübsch T; Rothanzlová S; Tomesová M; Spaniel F; Kitzlerová E
Cas Lek Cesk; 2010; 149(1):21-5. PubMed ID: 20662456
[TBL] [Abstract][Full Text] [Related]
9. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia.
Csernansky JG; Mahmoud R; Brenner R;
N Engl J Med; 2002 Jan; 346(1):16-22. PubMed ID: 11777998
[TBL] [Abstract][Full Text] [Related]
10. Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder.
Fu DJ; Turkoz I; Simonson RB; Walling DP; Schooler NR; Lindenmayer JP; Canuso CM; Alphs L
J Clin Psychiatry; 2015 Mar; 76(3):253-62. PubMed ID: 25562685
[TBL] [Abstract][Full Text] [Related]
11. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
[TBL] [Abstract][Full Text] [Related]
12. A program for relapse prevention in schizophrenia: a controlled study.
Herz MI; Lamberti JS; Mintz J; Scott R; O'Dell SP; McCartan L; Nix G
Arch Gen Psychiatry; 2000 Mar; 57(3):277-83. PubMed ID: 10711914
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia: A Randomized Clinical Trial.
Berwaerts J; Liu Y; Gopal S; Nuamah I; Xu H; Savitz A; Coppola D; Schotte A; Remmerie B; Maruta N; Hough DW
JAMA Psychiatry; 2015 Aug; 72(8):830-9. PubMed ID: 25820612
[TBL] [Abstract][Full Text] [Related]
14. Relapse prevention through health technology program reduces hospitalization in schizophrenia.
Homan P; Schooler NR; Brunette MF; Rotondi A; Ben-Zeev D; Gottlieb JD; Mueser KT; Achtyes ED; Gingerich S; Marcy P; Meyer-Kalos P; Hauser M; John M; Robinson DG; Kane JM
Psychol Med; 2023 Jul; 53(9):4114-4120. PubMed ID: 35634965
[TBL] [Abstract][Full Text] [Related]
15. Early intervention in psychotic relapse.
Birchwood M; Spencer E
Clin Psychol Rev; 2001 Nov; 21(8):1211-26. PubMed ID: 11702513
[TBL] [Abstract][Full Text] [Related]
16. Financial incentives for improving adherence to maintenance treatment in patients with psychotic disorders (Money for Medication): a multicentre, open-label, randomised controlled trial.
Noordraven EL; Wierdsma AI; Blanken P; Bloemendaal AF; Staring AB; Mulder CL
Lancet Psychiatry; 2017 Mar; 4(3):199-207. PubMed ID: 28236956
[TBL] [Abstract][Full Text] [Related]
17. Schizophrenia prediction with the adaboost algorithm.
Hrdlicka J; Klema J
Stud Health Technol Inform; 2011; 169():574-8. PubMed ID: 21893814
[TBL] [Abstract][Full Text] [Related]
18. Smartphone-Enhanced Symptom Management In Psychosis: Open, Randomized Controlled Trial.
Lewis S; Ainsworth J; Sanders C; Stockton-Powdrell C; Machin M; Whelan P; Hopkins R; He Z; Applegate E; Drake R; Bamford C; Roberts C; Wykes T
J Med Internet Res; 2020 Aug; 22(8):e17019. PubMed ID: 32788150
[TBL] [Abstract][Full Text] [Related]
19. [Prodromal symptoms in schizophrenic relapse: A descriptive and comparative study].
Bouhlel S; Jones Y; Khelifa E; Msolly M; Melki W; El-Hechmi Z
Encephale; 2012 Oct; 38(5):397-403. PubMed ID: 23062453
[TBL] [Abstract][Full Text] [Related]
20. Developing Texting for Relapse Prevention: A Scalable mHealth Program for People With Schizophrenia and Schizoaffective Disorder.
Ybarra ML; Rodriguez K; Madison H; Mojtabai R; Cullen BA
J Nerv Ment Dis; 2019 Oct; 207(10):854-862. PubMed ID: 31503175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
